NSE: MANKIND · 30 September 2026 · Dated market coverage
- The stock is -1.62% at ₹2,503.80.
- Likely reason:Sector-led pullback with elevated trading volume
- Approximate traded value is₹325.98 crore.
- It is -5.23% from its 52-week high and +31.11% from its 52-week low.
- The stock is being compared withNifty Pharmaalongside the Nifty 50.
Why Is Mankind Pharma Share Price Falling 1.62% Today?
Latest NSE EOD report: 2026-09-29. Today’s Volume: 1,301,940; 5-Day Avg. Volume: 891,018; 20-Day Avg. Volume: 521,289; Volume vs 20-Day Avg.: 2.50x; Delivery Quantity: 697,782; Delivery %: 35.35%; Number of Trades: 84,454.
Mankind Pharma fell 1.62% during the session, closing at ₹2503.80 after moving within a day’s range of ₹2455.00 and ₹2552.00. Trading volume was noticeably elevated, recording 1.3 million shares traded, which is 2.5 times the 20-day average volume, pointing to increased market participation during the pullback.
The broader market and pharmaceutical segment experienced downward pressure, with the Nifty falling 0.42% and the Nifty Pharma sector index dropping 1.84%. Mankind Pharma’s decline tracked the weak broader pharmaceutical space closely, reflecting sector-wide headwinds rather than an isolated drop.
Recent corporate updates show the company proceeding with the voluntary liquidation and integration of its material wholly-owned subsidiary, Bharat Serums and Vaccines Limited, alongside recent statutory auditor changes within that subsidiary. While these structural realisations provide ongoing operational context, no single direct corporate trigger was reported to account for today’s specific price movement.
low confidence
- Nifty Pharma sector index fell 1.84%
- Trading volume reached 2.5 times the 20-day average
Ownership & Transaction Activity
Completion of Realignment of Security Cover in respect of Non-ConvertibleDebentures and Consequent Release of Pledged Shares of Bharat Serums andVaccines Limited
Source: NSE corporate filing
- Promoter group submitted disclosures under Regulation 31(4) of SEBI Takeover Regulations confirming zero encumbrances for FY ending March 31, 2026.
- Security cover realignment for non-convertible debentures resulted in the release of pledged shares of Bharat Serums and Vaccines Limited in August 2026.
Source: NSE corporate disclosure. Only factual ownership/shareholding details extracted from the filing are shown.
WittyTrades Data Insight
Price Position:The stock is around the middle of the day’s trading range.
Move From Open:-1.44%.
Intraday Range:3.81% of the previous close.
5-Day Performance:+1.57%; 20-Day Performance:+4.70%.
Latest Company Developments
What Should Traders and Investors Watch Next?
- Progress updates regarding the voluntary liquidation and integration of Bharat Serums and Vaccines Limited
- Delivery volume trends following the higher-than-average turnover observed today
- Performance of the Nifty Pharma sector benchmark for continued directional cues
- Execution progress on the newly in-licensed insulin product portfolio
Catalyst note:No single confirmed company-specific trigger caused today’s move; the decline aligns with broader sector weakness amid higher volume.
Frequently Asked Questions
What is the likely reason for today’s move?
The stock declined alongside a weak broader pharmaceutical sector while recording heavier-than-average volume. No immediate single catalyst was confirmed for today’s price action.
Is trading volume elevated?
Today’s volume is 1,301,940. The latest 20-day average available is 521,289, equivalent to about 2.50x of the recent average.
Before acting on this stock
Consult your own investment adviser before acting on any security. If you are interested in stock research or other available research categories, review theWittyTrades subscription plans and research segments.
Article by:WittyTrades Research Desk